Gilead Sciences, Inc. (GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1.PURPOSE 1 is a phase III, double-blind, randomized study evaluating the safety and efficacy of twice-yearly, subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) and once-daily oral Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg; F/TAF) in more than 5,300 cisgender women and adolescent girls aged 16-25 years across 25 sites in South Africa and three sites in Uganda.B ...

Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its Phase 3 HIV prevention trial, marking the first trial showing zero infections. Given the stock's underperformance this year, this news is a significant relief for investors. Let's delve into the trial's details, the stock's recent performance, and its future prospects.Get Gilead Sciences alerts:Gilead's Lenacapa ...

Gilead Sciences (GILD) shares soared 8.5% in the last trading session to close at $68.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.The surge is mostly attributable to positive results from the late study PURPOSE 1 wherein twice-yearly lenacapavir demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy.  On the basis of these results, ...

Key TakeawaysA Phase 3 trial of Gilead's injectable drug lenacapavir found it was 100% effective in preventing HIV infection in women. Gilead said the test results were so significant an independent monitor recommended the company give the drug to all participants.More testing is needed before Gilead can apply to the U.S. Food and Drug Administration for approval.Shares of Gilead surged Thursday following the news. Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announ ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Both GILD and JAZZ are lower in 2024 and way off their record highs from 2015Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level. Amidst this choppiness, two pharmaceutical stocks are worth a closer look today; Gilead Sciences, Inc. (NASDAQ:GILD) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ).GILD is up 9.% to trade at $69.10, on track for its biggest single-session pop since Oct. 2022. The pharma giant repo ...

Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.None of the roughly 2,000 women in the trial who received Gilead's shot lenacapavir had contracted HIV by an interim analysis, prompting the independent data monitoring committee to recommend Gilead unblind the Phase 3 trial and offer the treatment to everyone in the study. Other participants had received standard daily pills.The results bring Gilead one step closer to introducing a ...

Gilead Sciences (GILD) closed at $63.56 in the latest trading session, marking a -1.21% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.23%. Elsewhere, the Dow saw a downswing of 0.17%, while the tech-heavy Nasdaq appreciated by 0.34%.The HIV and hepatitis C drugmaker's stock has dropped by 3.98% in the past month, falling short of the Medical sector's gain of 2.69% and the S&P 500's gain of 3.96%.Analysts and investors alike will be keeping a close eye on the perf ...

Grant & Eisenhofer, Jenner Law, Burg Simpson, and The Lawrence Law Firm are jointly issuing the following public statement following Gilead’s June 4th press release reported in the San Francisco Chronicle SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- In a recent press release (reported in The San Francisco Chronicle on June 4th), California pharma giant Gilead touts a $40 million settlement to resolve the lawsuits of approximately 2,625 plaintiffs. At the same time, it brushes off its culpability for del ...

Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 1:20 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thank you so much for joining. We're really pleased to have the Gilead team who has joined us virtually, unfortunately, due to the weather. It was hard to make it here in person. With us, we have Dan O'Day, Chairman and ...